Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells

Koutsimpelas,Dimitrios; Pongsapich,Warut; Heinrich,Ulf; Mann,Sylvia; Mann,Wolf  J.; Brieger,Jürgen

doi:10.3892/or.2012.1624

Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells

Authors:
- Dimitrios Koutsimpelas
- Warut Pongsapich
- Ulf Heinrich
- Sylvia Mann
- Wolf J. Mann
- Jürgen Brieger
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany
Published online on: January 9, 2012 https://doi.org/10.3892/or.2012.1624
Pages: 1135-1141

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Promoter hypermethylation of tumor suppressor genes (TSGs) is a common feature of primary cancer cells. However, to date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis have not been well-defined. In the present study, we analyzed the promoter methylation status of the genes mutL homolog 1 (MLH1), Ras-association domain family member 1 (RASSF1A) and O-6-methylguanine-DNA methyltransferase (MGMT) in 23 HNSCC samples, three control tissues and one HNSCC cell line (UM-SCC 33) using methylation-specific PCR (MSP). The expression of the three proteins was quantified by semi-quantitative immunohistochemical analysis. The cell line was treated with the demethylating agent 5-azacytidine (5-Aza) and the methylation status after 5-Aza treatment was analyzed by MSP and DNA sequencing. Proliferation was determined by Alamar blue staining. We found that the MGMT promoter in 57% of the analyzed primary tumor samples and in the cell line was hypermethylated. The MLH promoter was found to be methylated in one out of 23 (4%) tumor samples while in the examined cell line the MLH promoter was unmethylated. The RASSF1A promoter showed methylation in 13% of the tumor samples and in the cell line. MGMT expression in the group of tumor samples with a hypermethylated promoter was statistically significantly lower compared to the group of tumors with no measured hypermethylation of the MGMT promoter. After treatment of the cell line with the demethylating agent 5-Aza no demethylation of the methylated MGMT and RASSF1A genes were determined by MSP. DNA sequencing verified the MSP results, however, increased numbers of unmethylated CpG islands in the promoter region of MGMT and RASSF1A were observed. Proliferation was significantly (p<0.05) reduced after treatment with 5-Aza. In summary, we have shown promoter hypermethylation of the tumor suppressor genes MGMT and RASSF1A in HNSCC, suggesting that this epigenetic inactivation of TSGs may play a role in the development of HNSCC. 5-Aza application resulted in partial demethylation of the MGMT and RASSF1A TSGs and reduced proliferation of the tumor cells suggesting further evaluation of 5-Aza for HNSCC treatment.

View Figures

View References

1	Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med. 328:184–194. 1993. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
3	Gollin SM: Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck. 23:238–253. 2001. View Article : Google Scholar : PubMed/NCBI
4	Brieger J, Jacob R, Riazimand HS, Essig E, Heinrich UR, Bittinger F and Mann WJ: Chromosomal aberrations in premalignant and malignant squamous epithelium. Cancer Genet Cytogenet. 144:148–155. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ha PK and Califano JA: Promoter methylation and inactivation of tumour suppressor genes in oral squamous cell carcinoma. Lancet Oncol. 7:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
6	Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.PubMed/NCBI
7	Brieger J, Pongsapich W, Mann SA, Hedrich J, Fruth K, Pogozelski B and Mann WJ: Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma. Oral Oncol. 46:678–683. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER and Latif F: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer. 38:1585–1592. 2002. View Article : Google Scholar
9	Viswanathan M, Tsuchida N and Shanmugam G: Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer. 105:41–46. 2003. View Article : Google Scholar
10	Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M and Shibata T: Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol. 132:735–743. 2006. View Article : Google Scholar : PubMed/NCBI
11	van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, Venkitaraman AR, Arends MJ and Bradley A: The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol. 25:8356–8367. 2005.PubMed/NCBI
12	Jiricny J and Nyström-Lahti M: Mismatch repair defects in cancer. Curr Opin Genet Dev. 10:157–161. 2000. View Article : Google Scholar
13	Pegg AE: Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:6119–6129. 1990.PubMed/NCBI
14	Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
15	Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, et al: Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66:3338–3344. 2006. View Article : Google Scholar : PubMed/NCBI
16	Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA and Lubbert M: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood. 100:2957–2964. 2002.PubMed/NCBI
17	Ruter B, Wijermans PW and Lubbert M: DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukaemia. Int J Hematol. 80:128–135. 2004. View Article : Google Scholar : PubMed/NCBI
18	Welkoborsky HJ, Jacob R, Riazimand SH, Bernauer HS and Mann WJ: Molecular biologic characteristics of seven new cell lines of squamous cell carcinomas of the head and neck and comparison to fresh tumor tissue. Oncology. 65:60–71. 2003. View Article : Google Scholar : PubMed/NCBI
19	Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL and Lai SY: Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 29:163–188. 2007. View Article : Google Scholar : PubMed/NCBI
20	Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
21	Nan HM, Song YJ, Yun HY, Park JS and Kim H: Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol. 11:3834–3841. 2005.PubMed/NCBI
22	Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
23	Gosepath J, Brieger J, Lehr HA and Mann WJ: Expression, localization and significance of vascular permeability/vascular endothelial growth factor in nasal polyps. Am J Rhinol. 19:7–13. 2005.PubMed/NCBI
24	Ahmed SA, Gogal RM and Walsh JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [³H]thymidine incorporation assay. J Immunol Methods. 170:211–224. 1994.PubMed/NCBI
25	Liu K, Zuo C, Luo QK, Suen JY, Hanna E and Fan CY: Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. Diagn Mol Pathol. 12:50–56. 2003. View Article : Google Scholar : PubMed/NCBI
26	Steinmann K, Sandner A, Schagdarsurengin U and Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 22:1519–1526. 2009.PubMed/NCBI
27	Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G and Tokino T: Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res. 8:3164–3171. 2002.PubMed/NCBI
28	Wang Y, Irish J, MacMillan C, Brown D, Xuan Y, Boyington C, Gullane P and Kamel-Reid S: High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: lack of involvement of the mismatch repair genes hMLH1 and hMSH2. Int J Cancer. 93:353–360. 2001. View Article : Google Scholar : PubMed/NCBI
29	Wright CL and Stewart ID: Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol. 27:1393–1406. 2003. View Article : Google Scholar : PubMed/NCBI
30	Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T and Maehara Y: Loss of protein expression of hMLH1 and hMSH2 with double primary carcinomas of the stomach and colorectum. Oncol Rep. 16:41–47. 2006.PubMed/NCBI
31	Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V and Ben-Yehuda D: Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 15:206–213. 2009. View Article : Google Scholar : PubMed/NCBI
32	Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI and Sidransky D: Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res. 9:3635–3640. 2003.PubMed/NCBI
33	Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ and Huang DP: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 61:3877–3881. 2001.PubMed/NCBI
34	Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP and Fan CY: O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 13:967–975. 2004.PubMed/NCBI
35	Paluszczak J, Misiak P, Wierzbicka M, WoŸniak A and Baer-Dubowska W: Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol. 47:104–107. 2011. View Article : Google Scholar : PubMed/NCBI
36	Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, et al: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 94:26–32. 2002. View Article : Google Scholar : PubMed/NCBI
37	Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar
38	Park TJ, Han SU, Cho YK, Paik WK, Kim YB and Lim IK: Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 92:2760–2768. 2001. View Article : Google Scholar : PubMed/NCBI
39	Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 21:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
40	Shen WJ, Dai DQ, Teng Y and Liu HB: Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol. 14:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
41	Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 24:132–138. 2000. View Article : Google Scholar : PubMed/NCBI
42	Karpf AR and Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 21:5496–5503. 2002. View Article : Google Scholar : PubMed/NCBI